drugset / Trial / NCT06881017
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, umbrella-design, Phase II clinical trial. Eligible participants with advanced or metastatic gastric cancer who are treatment-naïve for advanced-stage systemic therapy will undergo biomarker profiling (HER2, CLDN18.2, and PD-L1) via next-generation sequencing (NGS) or immunohistochemistry (IHC). Participants will be stratified into distinct molecular subtypes and assigned subtype-specific therapeutic regimens. The primary objectives are to assess treatment efficacy (e.g., objective response rate) and safety profiles across molecularly defined cohorts.
Timeline
- Start
- 2025-05-01
- Primary completion
- 2029-08-01
- Completion
- 2029-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | Intravenous |
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Oxaliplatin | Small molecule | — | Intravenous |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | Intravenous |
| Subject | Rivoceranib | Small molecule | — | Oral |
| Subject | S-1 | Small molecule | — | Oral |
| Subject | SHR-A1811 | Monoclonal antibody | — | Intravenous |
| Subject | SHR-A1904 | Unknown | — | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |
| Subject | zolbetuximab | Monoclonal antibody | — | Intravenous |